Tregs accumulation in the TME is associated with poor clinical prognosis in cancer patients [40–42] and is one of the factors that impairs the efficacy of the treatment with checkpoint inhibitors targeting the PD-1/PD-L1 pathway [43–45]. Here, CD274 is linked to cancer.